GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » Other Cash Receipts from Operating Activities

Sino Biopharmaceutical (FRA:SMZ1) Other Cash Receipts from Operating Activities


View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical Other Cash Receipts from Operating Activities?

Other Cash Receipts from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Sino Biopharmaceutical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » Other Cash Receipts from Operating Activities
Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.